查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370887

狼瘡治療市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按治療類型、給藥途徑、最終用戶、地區、競爭細分

Lupus Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Treatment Type, By Route of Administration, By End User, By Region, By Competition
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計全球狼瘡治療市場在 2024-2028 年預測期內將出現強勁成長。全球狼瘡治療市場的主要驅動力之一是該疾病盛行率的不斷上升。當人體的免疫系統攻擊自身的組織和器官時，就會引發自體免疫疾病狼瘡。狼瘡相關發炎會影響多種身體功能，包括關節、皮膚、腎臟、血球、大腦、心臟和肺部。由於狼瘡的徵兆和症狀與其他疾病相似，因此診斷起來很困難。在許多（但不是全部）狼瘡病例中，最明顯的狼瘡症狀是臉部皮疹，看起來像蝴蝶翅膀在雙頰上展開。有些人從出生就容易罹患狼瘡，這可能是由疾病、藥物甚至陽光引起的。據美國狼瘡基金會稱，全世界至少有 500 萬人患有某種形式的狼瘡，並且這種疾病在 15-44 歲年齡層的人群中更為普遍。

狼瘡盛行率的增加推動了狼瘡治療市場的成長

市場概況
預測期 2024-2028
2022 年市場規模 20.5億美元
2028 年市場規模 28.9億美元
2023-2028 年年複合成長率 5.84%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

由於全球狼瘡病例不斷增加，狼瘡治療市場預計將成長。狼瘡盛行率上升的原因尚不完全清楚，但研究已經確定了幾個潛在因素。根據美國狼瘡基金會的數據，每 10 名患有狼瘡的成年人中有 9 名是女性。關鍵因素之一是遺傳。研究表明，某些遺傳變異會增加罹患狼瘡的風險。例如，具有 IRF5 基因特定變異的人更有可能患上狼瘡。然而，僅靠遺傳學無法解釋狼瘡盛行率的增加。環境因素也扮演重要角色。污染、毒素和傳染源等環境因素與狼瘡的發生有關。接觸某些化學物質和污染物（例如二氧化矽）已被證明會增加罹患狼瘡的風險，從而導致全球狼瘡治療市場的擴大。此外，EB病毒和鉅細胞病毒等感染也與狼瘡的發病有關。生活方式和飲食的改變也可能導致狼瘡盛行率上升。根據一篇研究文章“系統性紅斑狼瘡的全球流行病學：全面的系統分析和建模研究”，系統性紅斑狼瘡（SLE）是最常見的狼瘡類型。一般人群中 SLE 的發生率從中亞每 10 萬人年 1.18（0.16 至 3.68）到中歐每 10 萬人年 13.74（3.2 至 31.82）不等。 SLE 發生率估計最高的四個國家是波蘭，其次是美國、巴貝多和中國。加工食品含量高、營養成分含量低的飲食會增加體內炎症，進而引發狼瘡等自體免疫疾病。此外，久坐的生活方式和肥胖與患狼瘡的風險增加有關，預計這將擴大全球狼瘡治療市場。據世界心臟聯合會稱，到 2025 年，可能有 27 億成年人超重或肥胖。

藥物發現的不斷成長的研究和開發推動了全球狼瘡治療市場

狼瘡是一種複雜的疾病，會影響身體的各個部位，例如皮膚、關節、腎臟和肺部。雖然有治療方法可以控制狼瘡症狀，但無法治癒。因此，增加狼瘡治療的研發（R＆D）工作對於改善患者的治療結果和生活品質並導致全球狼瘡治療市場的成長至關重要。開發狼瘡新療法的主要挑戰之一是疾病的複雜性。狼瘡是一種多因素疾病，這意味著有許多因素導致其發生和進展。這些因素包括遺傳、環境和荷爾蒙因素。儘管面臨挑戰，近年來人們對開發狼瘡新療法的興趣日益濃厚。原因之一是人們對該疾病的潛在機制的了解不斷加深。基因研究和技術的進步使研究人員能夠識別出參與狼瘡發生和進展的特定基因和途徑。這些知識導致了針對這些特定基因和途徑的新藥的開發。人們對狼瘡治療越來越感興趣的另一個原因是對新療法的需求不斷成長。雖然目前有針對狼瘡的治療方法，但它們並不總是對所有患者有效，而且許多方法都有明顯的副作用。因此，需要新的和改進的療法來有效控制狼瘡症狀，同時最大限度地減少副作用，從而促進全球狼瘡治療市場的成長。研究人員和產業之間的合作有助於彌合基礎研究和臨床開發之間的差距，並加速新療法的開發。透過共同努力，研究人員利用業界的專業知識和資源來開發新的藥物和療法，從而導致全球對狼瘡治療的巨大需求。除了資金和合作之外，還可以利用技術進步來增加狼瘡治療的研發工作。例如，人工智慧和機器學習的進步有助於識別新的藥物標靶並加速藥物發現過程。同樣，基因編輯和基因治療的進步有助於開發更有針對性和個人化的狼瘡療法，預計這將推動全球狼瘡治療市場的成長。截至 2023 年 5 月 9 日，根據 ClinicalTrials.gov，全球約有 278 項與狼瘡治療相關的研究處於不同的開發階段。

合併、收購與合作

2021 年 6 月，Progentec 與葛蘭素史克 (GlaxoSmithKline, plc) 合作簽訂了一項為期 18 個月的協議，研究新的系統性紅斑狼瘡 (SLE 或狼瘡) 測量和管理工具。

2023年1月，EVOQ Therapeutics 與吉利德科學公司啟動了合作和授權協議，以推進後者的技術並創造治療狼瘡的免疫療法。根據協議條款，兩家公司將合作推進 RA 和狼瘡免疫療法的臨床前開發。

市場區隔

全球狼瘡治療市場根據治療類型、給藥途徑和最終用戶進行細分。根據治療類型，全球狼瘡治療市場分為非類固醇抗發炎藥、皮質類固醇、抗瘧藥、免疫抑制劑、生物製劑和其他。根據給藥途徑，全球狼瘡治療市場分為口服、靜脈注射和皮下注射。根據最終用戶，全球狼瘡治療市場分為醫院和診所、門診護理中心和其他。

市場參與者

葛蘭素史克公司、諾華公司、阿斯特捷利康公司、羅氏公司、禮來公司。 ImmuPharma PLC、輝瑞公司、賽諾菲公司、百時美施貴寶公司、默克公司是全球狼瘡治療市場的主要參與者。

報告範圍：

在本報告中，除了以下詳細介紹的產業趨勢外，全球狼瘡治療市場也分為以下幾類：

狼瘡治療市場，依治療類型：

  • 非類固醇抗發炎藥
  • 皮質類固醇
  • 抗瘧藥
  • 免疫抑制劑
  • 生物製劑
  • 其他

狼瘡治療市場，依給藥途徑：

  • 口服
  • 靜脈
  • 皮下

狼瘡治療市場，依最終用戶分類：

  • 醫院和診所
  • 門診護理中心
  • 其他

狼瘡治療市場，按地區：

  • 歐洲
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙
  • 亞太
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 土耳其

競爭格局

  • 公司概況：全球狼瘡治療市場主要公司的詳細分析。

可用的客製化：

  • 根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：COVID-19 對全球狼瘡治療市場的影響

第 6 章：臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成的臨床試驗
  • 終止的臨床試驗
  • 按開發階段分類的管道細目
  • 管道細分（按狀態）
  • 按研究類型分類的管道細目
  • 按地區分類的管道明細
  • 臨床試驗熱圖

第 7 章：全球狼瘡治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療類型（非類固醇抗發炎藥、皮質類固醇、抗瘧藥、免疫抑制劑、生物製劑、其他）
    • 依給藥途徑（口服、靜脈注射、皮下注射）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖
    • 按治療類型
    • 依給藥途徑
    • 按最終用戶
    • 按地區

第 8 章：北美狼瘡治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療類型
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 9 章：歐洲狼瘡治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療類型
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利

第 10 章：亞太地區狼瘡治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療類型
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 11 章：南美洲狼瘡治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療類型
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 12 章：中東和非洲狼瘡治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按治療類型
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非狼瘡治療公司
    • 沙烏地阿拉伯狼瘡治療公司
    • 阿拉伯聯合大公國狼瘡治療公司
    • 土耳其狼瘡治療

第 13 章：市場動態

  • 促進要素
  • 挑戰

第 14 章：市場趨勢與發展

  • 產品發布
  • 併購
  • 最近的發展

第 15 章：全球狼瘡治療市場：SWOT 分析

第16章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第17章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • GlaxoSmithKline, plc.
    • Novartis AG
    • AstraZeneca, plc.
    • F. Hoffmann-La Roche AG
    • Eli Lilly and Company
    • ImmuPharma PLC
    • Pfizer, Inc.
    • Sanofi SA
    • Bristl Myers Squibb Company
    • Merck & Co., Inc.

第 18 章：策略建議

第 19 章：關於我們與免責聲明

簡介目錄
Product Code: 15074

Global Lupus Therapeutics Market is anticipated to witness formidable growth in the forecast period, 2024-2028. One of the key drivers of the global lupus therapeutics market is the increasing prevalence of the disease. The autoimmune disease lupus is brought on when the body's immune system attacks its own tissues and organs. Lupus-related inflammation can impact a variety of bodily functions, including joints, skin, kidneys, blood cells, brain, heart, and lungs. Because of how frequently its signs and symptoms resemble those of other illnesses, lupus can be challenging to diagnose. In many but not all cases of lupus, the most recognizable lupus symptom is a facial rash that looks like butterfly wings unfolding across both cheeks. Some people are predisposed to lupus from birth, which can be brought on by illnesses, medications, or even sunlight. According to Lupus Foundation of America, at least five million people worldwide have a form of lupus and the disease is more prevalent among the people belonging to age group 15-44.

Lupus has no known cure, but treatments can help manage symptoms. The market for lupus therapeutics is also being driven by advancements in technology and the development of new drugs. There are currently only a few FDA-approved drugs for the treatment of lupus, but there are many promising drugs in the pipeline, propelling the growth of Global Lupus Therapeutics Market. In addition to traditional pharmaceuticals, there are also emerging therapies for lupus, such as gene therapy and stem cell therapy. These therapies have the potential to provide long-term relief from lupus symptoms and could be a game-changer in the treatment of the disease, leading to the expansion of Global Lupus Therapeutics Market. Apart from these, favorable government policies for developing Lupus Therapeutics and technological advancement for new applications propel the Global Lupus Therapeutics Market in the forecasted period. While there is currently no cure for lupus, several therapies are available to manage symptoms and prevent complications. The choice of therapy depends on the patient's symptoms, medical history, and other factors which are expected to grow Global Lupus Therapeutics Market.

Increasing Prevalence of Lupus propels the market growth for Lupus Therapeutics

Market Overview
Forecast Period2024-2028
Market Size 2022USD2.05 Billion
Market Size 2028USD2.89 Billion
CAGR 2023-20285.84%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

The market for Lupus Therapeutics is anticipated to grow due to the rising cases of Lupus worldwide. The reasons behind the rising prevalence of lupus are not yet fully understood, but research has identified several potential factors. According to Lupus Foundation of America, 9 out of 10 adults who are suffering from lupus are women. One of the key factors is genetics. Studies have shown that certain genetic variations can increase the risk of developing lupus. For example, people with a specific variation in the gene known as IRF5 are more likely to develop lupus. However, genetics alone cannot explain the increasing prevalence of lupus. Environmental factors also play a significant role. Environmental factors such as pollution, toxins, and infectious agents have been linked to the development of lupus. Exposure to certain chemicals and pollutants, such as silica, has been shown to increase the risk of developing lupus, leading to the expansion of Global Lupus Therapeutics Market. Additionally, infections such as Epstein-Barr virus and cytomegalovirus have been linked to the onset of lupus. Changes in lifestyle and diet may also be contributing to the rising prevalence of lupus. According to a research article, "Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study", Systemic lupus erythematosus (SLE), is the most common type of lupus. The incidence of SLE in the general population varied from 1.18 (0.16 to 3.68) per 100 000 person-years in central Asia to 13.74 (3.2 to 31.82) per 100 000 person-years in central Europe. The top four countries with the highest estimates of SLE incidence were Poland followed by United States, Barbados, and China. A diet high in processed foods and low in nutrients can increase inflammation in the body, which can trigger autoimmune diseases such as lupus. Additionally, sedentary lifestyles and obesity have been linked to an increased risk of developing lupus, which is expected to expand Global Lupus Therapeutics Market. According to the World Heart Federation, by 2025, 2.7 billion adults might be overweight or obese.

Rising Research and Development in Drug Discovery drives Global Lupus Therapeutics Market

Lupus is a complex disease that can affect various parts of the body, such as the skin, joints, kidneys, and lungs. While there are treatments available to manage the symptoms of lupus, there is no cure. Therefore, increasing research and development (R&D) efforts for lupus therapeutics is crucial to improve patient outcomes and quality of life and leading to the growth of Global Lupus Therapeutics Market. One of the main challenges in developing new therapeutics for lupus is the complex nature of the disease. Lupus is a multifactorial disease, meaning that there are many factors that contribute to its development and progression. These factors include genetic, environmental, and hormonal factors. Despite the challenges, there has been a growing interest in developing new therapeutics for lupus in recent years. One reason for this is the increasing understanding of the underlying mechanisms of the disease. Advances in genetic research and technology have allowed researchers to identify specific genes and pathways that are involved in the development and progression of lupus. This knowledge has led to the development of new drugs that can target these specific genes and pathways. Another reason for the increasing interest in lupus therapeutics is the growing demand for new treatments. While there are currently treatments available for lupus, they are not always effective for all patients, and many have significant side effects. Therefore, there is a need for new and improved therapies that can effectively manage the symptoms of lupus while minimizing side effects, hence augmenting the growth of Global Lupus Therapeutics Market. Collaboration between researchers and industry helps bridge the gap between basic research and clinical development and accelerate the development of new therapeutics. By working together, researchers leverage the expertise and resources of industry to develop new drugs and therapies leading to the huge demand for lupus therapeutics globally. In addition to funding and collaboration, there are also technological advancements that are leveraged to increase R&D efforts for lupus therapeutics. For example, advances in artificial intelligence and machine learning help to identify new drug targets and accelerate the drug discovery process. Similarly, advances in gene editing and gene therapy have helped in the development of more targeted and personalized therapies for lupus, which is expected to propel the growth of Global Lupus Therapeutics Market. As of 9th May 2023, as per clinicaltrials.gov, there are around 278 studies in different phases of development related to Lupus Therapeutics worldwide.

Mergers, Acquisitions and Collaborations

In June 2021, Progentec collaborated with GlaxoSmithKline, plc for an 18-month agreement to research new systemic lupus erythematosus (SLE or lupus) measurement and management tools.

In January 2023, EVOQ Therapeutics launched its collaboration and licensing agreement with Gilead Sciences to advance the latter's technology and create immunotherapies for the treatment of lupus. In accordance with the terms of the agreement, the two businesses will collaborate to advance the preclinical development of immunotherapies for RA and lupus.

Market Segmentation

Global Lupus Therapeutics Market is segmented based on Treatment Type, Route of Administration and End-User. Based on Treatment Type, the global lupus therapeutics market is divided into NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics and Others. Based on Route of Administration, the global lupus therapeutics market is divided into Oral, Intravenous and Subcutaneous. Based on End-User, the global lupus therapeutics market is divided into Hospitals & Clinics, Ambulatory Care Centers and Others.

Market players

GlaxoSmithKline, plc., Novartis AG, AstraZeneca, plc., Hoffmann-La Roche AG, Eli Lilly and Company. ImmuPharma PLC, Pfizer, Inc., Sanofi S.A., Bristl Myers Squibb Company, Merck & Co., Inc. are the key players operating in the global lupus therapeutics market.

Report Scope:

In this report, Global Lupus Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Lupus Therapeutics Market, By Treatment Type:

  • NSAIDs
  • Corticosteroids
  • Antimalarials
  • Immunosuppressants
  • Biologics
  • Others

Lupus Therapeutics Market, By Route of Administration:

  • Oral
  • Intravenous
  • Subcutaneous

Lupus Therapeutics Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Lupus Therapeutics Market, By region:

  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • North America
  • United States
  • Canada
  • Mexico
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Turkey

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in Global Lupus Therapeutics Market.

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Lupus Therapeutics Market

6. Clinical Trial Analysis

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Breakdown of Pipeline, By Development Phase
  • 6.5. Breakdown of Pipeline, By Status
  • 6.6. Breakdown of Pipeline, By Study Type
  • 6.7. Breakdown of Pipeline, By Region
  • 6.8. Clinical Trials Heat Map

7. Global Lupus Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics, Others)
    • 7.2.2. By Route of Administration (Oral, Intravenous, Subcutaneous)
    • 7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 7.2.4. By Region
    • 7.2.5. By Company (2022)
  • 7.3. Market Map
    • 7.3.1. By Treatment Type
    • 7.3.2. By Route of Administration
    • 7.3.3. By End User
    • 7.3.4. By Region

8. North America Lupus Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Lupus Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By End User
    • 8.3.2. Canada Lupus Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By End User
    • 8.3.3. Mexico Lupus Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By End User

9. Europe Lupus Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. Germany Lupus Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By End User
    • 9.3.2. France Lupus Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By End User
    • 9.3.3. United Kingdom Lupus Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By End User
    • 9.3.4. Spain Lupus Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Treatment Type
        • 9.3.4.2.2. By Route of Administration
        • 9.3.4.2.3. By End User
    • 9.3.5. Italy Lupus Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Treatment Type
        • 9.3.5.2.2. By Route of Administration
        • 9.3.5.2.3. By End User

10. Asia-Pacific Lupus Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Lupus Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By End User
    • 10.3.2. India Lupus Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By End User
    • 10.3.3. Japan Lupus Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By End User
    • 10.3.4. South Korea Lupus Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Treatment Type
        • 10.3.4.2.2. By Route of Administration
        • 10.3.4.2.3. By End User
    • 10.3.5. Australia Lupus Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Treatment Type
        • 10.3.5.2.2. By Route of Administration
        • 10.3.5.2.3. By End User

11. South America Lupus Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Treatment Type
    • 11.2.2. By Route of Administration
    • 11.2.3. By End User
    • 11.2.4. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Lupus Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Treatment Type
        • 11.3.1.2.2. By Route of Administration
        • 11.3.1.2.3. By End User
    • 11.3.2. Argentina Lupus Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Treatment Type
        • 11.3.2.2.2. By Route of Administration
        • 11.3.2.2.3. By End User
    • 11.3.3. Colombia Lupus Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Treatment Type
        • 11.3.3.2.2. By Route of Administration
        • 11.3.3.2.3. By End User

12. Middle East and Africa Lupus Therapeutics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Treatment Type
    • 12.2.2. By Route of Administration
    • 12.2.3. By End User
    • 12.2.4. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Lupus Therapeutics Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Treatment Type
        • 12.3.1.2.2. By Route of Administration
        • 12.3.1.2.3. By End User
    • 12.3.2. Saudi Arabia Lupus Therapeutics Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Treatment Type
        • 12.3.2.2.2. By Route of Administration
        • 12.3.2.2.3. By End User
    • 12.3.3. UAE Lupus Therapeutics Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Treatment Type
        • 12.3.3.2.2. By Route of Administration
        • 12.3.3.2.3. By End User
    • 12.3.4. Turkey Lupus Therapeutics Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Treatment Type
        • 12.3.4.2.2. By Route of Administration
        • 12.3.4.2.3. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

  • 14.1. Product Launches
  • 14.2. Mergers & Acquisitions
  • 14.3. Recent Developments

15. Global Lupus Therapeutics Market: SWOT Analysis

16. Porter's Five Forces Analysis

  • 16.1. Competition in the Industry
  • 16.2. Potential of New Entrants
  • 16.3. Power of Suppliers
  • 16.4. Power of Customers
  • 16.5. Threat of Substitute Products

17. Competitive Landscape

  • 17.1. Business Overview
  • 17.2. Company Snapshot
  • 17.3. Products & Services
  • 17.4. Financials (In case of listed companies)
  • 17.5. Recent Developments
  • 17.6. SWOT Analysis
    • 17.6.1. GlaxoSmithKline, plc.
    • 17.6.2. Novartis AG
    • 17.6.3. AstraZeneca, plc.
    • 17.6.4. F. Hoffmann-La Roche AG
    • 17.6.5. Eli Lilly and Company
    • 17.6.6. ImmuPharma PLC
    • 17.6.7. Pfizer, Inc.
    • 17.6.8. Sanofi S.A.
    • 17.6.9. Bristl Myers Squibb Company
    • 17.6.10. Merck & Co., Inc.

18. Strategic Recommendations

19. About Us & Disclaimer